Placebo for AZD3427 or AZD3427 diluent

DRUG2 trials

Sponsors

AstraZeneca AB

Conditions

Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)Heart failure with reduced ejection fractionRenal impairment

Phase 1

A Phase 1b, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)

CompletedCTIS2024-513143-82-00

AstraZeneca ABHeart failure with reduced ejection fraction, Renal impairment

Start: 2024-10-15End: 2025-08-21Target: 12Updated: 2025-02-11

Phase 2

A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)

CompletedCTIS2022-502382-25-00

AstraZeneca ABHeart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)

Start: 2023-08-24End: 2025-08-25Target: 176Updated: 2025-10-02